KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial.

Stephane Kroudia Wasse, Sandrine Tienhan Dabakuyo-Yonli, David Gottlieb, Florence Cymbalista, Stephen Mulligan, Marc Maynadie, Thérèse Aurran-Schleinitz

BMC Cancer 25(1) 712

PMID40240989
PMCIDPMC12004742
DOI10.1186/s12885-025-13792-y
发表日期2025-04-16
入排依据:The record is an ancillary study from a Phase III trial, but its sole focus is on health-related quality of life, a secondary/safety endpoint, and does not report a primary or key secondary time-to-event efficacy endpoint like OS, PFS, or HR for such endpoints.
摘要

摘要

BACKGROUND: Within the French-Australian CLL6 RESIDUUM trial, an ancillary study aimed at assessing the health-related quality of life (HRQoL) of patients with chronic lymphocytic leukemia (CLL) receiving a two-year consolidation of lenalidomide (LEN) or observation (OBS) after classical immunochemotherapy leaving them with detectable residual disease. METHODS: Data from French patients involved in this the trial were used here. The EORTC QLQ-C30 version 3 questionnaire was completed by patients at baseline, and then at months 3, 6, 12, 18 and 24 after consolidation. Repeated measures mixed-effects models were used to assess HRQoL changes between baseline and each checkpoint for each HRQoL scale. RESULTS: Baseline data showed overall a good global health status with mean scores of 76.3 and 72.1 in the LEN and OBS arms respectively, on the 0-100 scale. At 12 months, LEN patients had significantly more diarrhea than OBS patients (p = 0.003) and social functioning was significantly impaired at month 18 (p = 0.05). A 10-point difference appeared in the LEN arm for dyspnea and digestive disorders from month 12 on. Multivariate analysis showed a deleterious effect of LEN on global health (p = 0.02) and functional scales (p = 0.003). CONCLUSION: This study provides HRQoL values in a French cohort of CLL patients in consolidation treatment. Supplementation with lenalidomide as consolidation therapy in CLL leads to late health deterioration, especially diarrhea, after 12 months of treatment. Quantitative assessment of HRQoL should be balanced against benefits in disease control to determine overall health benefits.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。